Unemployment Benefits for Millionaires, and More from CRS
Thousands of Americans who have a gross annual income of more than a million dollars have also been collecting unemployment benefits, according to IRS data compiled in a new report from the Congressional Research Service.
That description fits only a tiny fraction of a percent of those receiving unemployment benefits, and is obviously not typical of recipients of unemployment insurance. But neither does it violate any law. The issue has prompted pending legislation to restrict benefits based on income. See Receipt of Unemployment Insurance by Higher-Income Unemployed Workers (“Millionaires”), August 2, 2012.
A persistent controversy in Japan concerning a U.S. Marine base in Okinawa is reviewed in another new report from the Congressional Research Service. See The U.S. Military Presence in Okinawa and the Futenma Base Controversy, August 3, 2012.
Other new and updated CRS reports that CRS is not authorized to release to the public include the following.
Comprehensive Nuclear-Test-Ban Treaty: Background and Current Developments, August 3, 2012
U.S.-China Relations: Policy Issues, August 2, 2012
Uzbekistan: Recent Developments and U.S. Interests, August 3, 2012
Global Security Contingency Fund (GSCF): Summary and Issue Overview, August 1, 2012
Science, Technology, Engineering, and Mathematics (STEM) Education: A Primer, August 1, 2012
Continuing Resolutions: Overview of Components and Recent Practices, August 6, 2012
Department of Homeland Security: FY2013 Appropriations, August 3, 2012
Nuclear weapons budgeting is like agreeing to buying a house without knowing the sales price, the mortgage rate, or the monthly payment.
Employing a living approach to evidence synthesis, disseminated at a national level, is a streamlined way to enable evidence-based decision-making nationwide.
By providing essential funding mechanisms, the Bioeconomy Finance Program will reduce the risks inherent in biotechnology innovation, encouraging more private sector investment.
While the U.S. has made significant advancements and remained a global leader in biotechnology over the past decade, the next four years will be critical in determining whether it can sustain that leadership.